LivaNova Earnings Call Transcripts
Fiscal Year 2026
-
The meeting was held virtually with strong shareholder participation and all quorum requirements met. Ten resolutions covering director elections, compensation, auditor appointments, and share repurchase were presented, with final results to be published. No shareholder questions were received.
-
Management outlined sustained growth through reinvestment in core businesses, improved reimbursement, and manufacturing scale. VNS Therapy and Essenz upgrades are driving performance, while OSA and new product launches offer future upside. Margin discipline is maintained alongside strategic investments.
-
Q1 2026 saw 11% revenue growth, driven by strong cardiopulmonary and epilepsy performance, with upgraded full-year guidance reflecting robust demand and key regulatory milestones in OSA. Adjusted EPS and revenue outlooks were raised, and capital investments continue to support expansion.
-
The session highlighted strong core business performance, strategic focus on high-growth markets like OSA and DTD, and significant clinical and reimbursement milestones. OSA commercialization is set for rapid scaling, while improved CMS reimbursement and new clinical data are expected to drive further growth.
Fiscal Year 2025
-
Double-digit revenue and EPS growth in 2025 were driven by strong cardiopulmonary and epilepsy performance, margin expansion, and robust cash generation. 2026 guidance calls for 6%-7% revenue growth, continued innovation investment, and improved reimbursement supporting epilepsy growth.
-
Management outlined strong 2025 growth, with margin expansion funding OSA market entry and new product launches in CP and oxygenators. Major reimbursement gains in epilepsy will drive volume, while OSA and depression therapy benefit from operational synergies and strategic hiring.
-
Leadership is driving a portfolio transformation focused on innovation and entry into faster-growing, more profitable markets. Epilepsy and cardiopulmonary segments are set for steady growth, with new digital and hardware upgrades planned. Entry into sleep apnea leverages neuromodulation expertise, with prudent financial targets and flexibility to adjust investments as milestones are met.
-
A new five-year plan targets high single-digit plus revenue growth, margin expansion, and EPS CAGR in the low double-digits to mid-teens, driven by core cardiopulmonary and epilepsy businesses, and accelerated by OSA entry. OSA is expected to deliver $200M–$400M revenue by 2030, with DTD as a major upside pending CMS approval.
-
Delivered 13% organic revenue growth, margin expansion, and strong cash generation, led by cardiopulmonary and epilepsy segments. Raised 2025 guidance for revenue, EPS, and free cash flow, with major growth expected from ESSENCE in China and ongoing innovation investments.
-
Core businesses in neuromodulation and cardiopulmonary are driving strong, sustained growth, with new product launches and market share gains. Expansion into OSA and DTD, supported by clinical data and reimbursement progress, positions the company for long-term growth.
-
Double-digit growth continues, driven by cardiopulmonary and epilepsy segments, with strong market share gains and strategic pricing. Innovation in heart-lung machines and neuromodulation, plus upcoming reimbursement changes, position the business for further expansion.
-
Delivered 10% organic revenue growth and expanded operating margin, driven by strong cardiopulmonary and neuromodulation performance. Raised 2025 guidance for revenue, EPS, and free cash flow, with key clinical and regulatory milestones supporting future growth.
-
The meeting was held virtually, covering director elections, executive compensation, auditor appointments, and incentive plans. Quorum was met, voting was electronic, and no shareholder questions were received. Final voting results will be published online.
-
Management highlighted strong double-digit growth in core cardiopulmonary and epilepsy businesses, driven by innovation, pricing, and market share gains. Progress in OSA and DTD programs, robust clinical data, and regulatory advances position the company for expansion. Capital allocation will prioritize core, OSA, and neuromodulation growth.
-
Double-digit organic revenue growth in Q1 was driven by strong cardiopulmonary and neuromodulation performance, leading to a raised 2025 outlook. Key milestones included positive OSPREY trial data for OSA, resolution of the SNIA litigation, and robust cash flow, with manageable tariff impacts incorporated into guidance.
-
Double-digit organic growth continued in 2024, with strong momentum into 2025 and a focus on innovation and portfolio expansion. OSA and DTD programs are advancing, with key regulatory and commercialization decisions expected mid-year. SNIA litigation outcome remains a near-term financial variable.
Fiscal Year 2024
-
Delivered 11% organic revenue growth in 2024, with strong margin expansion and cash flow. Cardiopulmonary and epilepsy segments drove results, while innovation milestones in OSA and DTD set up future growth. 2025 guidance calls for 6%-7% organic revenue growth and 9% EPS growth at midpoint.
-
Strong Q3 results and raised guidance were highlighted, with Q4 growth expected to slow due to tough comps. Key growth drivers include market share gains, capacity expansion, and pricing, while pipeline initiatives in depression and sleep apnea show promise for future revenue.
-
Strong clinical data and differentiated design position the OSA device for FDA submission in 2025, with commercial launch likely in 2026. Cardiopulmonary growth is driven by increased demand and innovation, while epilepsy and depression segments focus on digitalization, reimbursement, and targeted growth strategies.
-
Leadership transitions and a focus on talent, execution, and innovation are driving strong growth in core cardiopulmonary and epilepsy businesses. Osprey trial results for OSA are promising, and strategic R&D rebalancing supports future pipeline and margin expansion.
-
Q3 2024 saw 11% revenue growth, margin expansion, and strong performance in both cardiopulmonary and epilepsy segments. Guidance for 2024 was raised, with continued investment in innovation and capacity, and margin growth expected to outpace revenue in 2025.
-
Leadership is focused on talent, innovation, and execution, driving sustained above-market growth. Strategic plans target core and adjacent markets, with a long-term outlook through 2030 and an analyst day planned for next year. Legal and reimbursement developments may impact execution but not core strategy.
-
Q2 2024 delivered 10% revenue growth and margin expansion, with strong cardiopulmonary and epilepsy performance. Full-year guidance for revenue and adjusted EPS was raised, while investment in the depression program will be reduced in 2025, improving profitability.
-
The virtual meeting confirmed quorum and introduced board members, with 89% of voting rights represented. Twelve resolutions were presented, including director elections, compensation, and auditor appointments. No shareholder questions were received.
-
The discussion outlined a three-pillar strategy focused on core business growth, advancing clinical innovations, and exploring future opportunities. While the RECOVER trial missed its primary endpoint, OSPREY for OSA showed strong interim results. Sustained growth in epilepsy and cardiopulmonary is driven by market penetration, innovation, and operational improvements.